DSIP (Delta Sleep-Inducing Peptide)
Delta sleep-inducing peptide; an endogenous peptide studied in older literature, not FDA-approved.
What it is
Delta sleep-inducing peptide is a naturally occurring peptide first isolated in the 1970s from studies of sleep physiology. The name oversells it: subsequent research on whether administering DSIP actually improves sleep produced decades of mixed, mostly older, mostly small studies.
It was never developed into an approved drug, and modern sleep medicine does not use it. Online sellers lean entirely on the evocative name and the vintage literature.
What researchers have actually studied it for
Sleep physiology in older research literature, with inconsistent findings; never developed into an approved therapy.
How it works
Genuinely unclear — half a century on, DSIP has no confirmed receptor. Proposed involvement spans sleep-regulatory circuits, stress-axis modulation and opioid-adjacent signaling, but the molecule's mechanism remains one of sleep science's loose ends, which suits its inconsistent effects.
The molecule itself
A nonapeptide (WAGGDASGE) — small, acidic, and mechanistically orphaned: no confirmed receptor in five decades. Proposed interactions span multiple systems without a settled target, which is chemically unusual for a molecule this old and this studied.
Where it came from
Swiss researchers isolated it in 1974 from the blood of sleeping rabbits — a genuinely elegant experiment — and named it for the delta-wave sleep it seemed to induce. Decades of follow-up produced conflicting results, the field moved on to orexin and GABA pharmacology, and DSIP became a historical footnote the gray market later revived.
The timeline
1974
Isolated in Switzerland from sleeping-rabbit blood dialysis experiments.
1970s–80s
Replication attempts produce the field's famous mixed results.
1980s
Side literatures explore stress hormones, pain, withdrawal — none consolidate.
1990s+
Sleep science moves to systems neuroscience; DSIP shelved.
2010s+
Wearable-era revival in gray-market sleep stacks.
What the research record actually contains
- 1970s–80s animal and small human studies with inconsistent sleep effects.
- Scattered explorations in pain and withdrawal, none conclusive.
- No modern controlled trials; no presence in sleep-medicine guidelines.
What could change this assessment
No active research program exists. Its only plausible scientific future is incidental — if stress-axis peptide work ever intersects its old findings. Commercially it will persist as long as sleep anxiety does.
What's known about risks
Old studies reported little acute toxicity; that is not a modern safety file. With no confirmed mechanism and no contemporary data, its risk profile is simply unwritten.
Where it stands legally
Never approved anywhere; research-chemical channel only.
Worth asking a licensed provider
- 1.Have we actually worked up my sleep problem — apnea screening, sleep hygiene, CBT-I?
- 2.Why would a compound abandoned by sleep science help where evaluated treatments haven't been tried?
- 3.What proven options fit my specific sleep complaint?
Common claims, corrected
“It induces delta sleep — it's in the name.”
Reality: The name records one 1974 experiment, not a replicated effect. Five decades of follow-up produced inconsistency, no receptor, and no clinical role.
“Modern science just hasn't gotten around to it.”
Reality: Science got around to it for twenty years and moved on — the null pattern was the result, not neglect.
DSIP (Delta Sleep-Inducing Peptide) FAQ
Does DSIP actually help you sleep?
The older literature is genuinely mixed — some small studies reported effects, others none. No modern controlled trials settle it, and no sleep-medicine guideline includes it.
Is DSIP natural?
The peptide occurs naturally in the body. As always, that says nothing about whether injecting a synthetic version from an unregulated source is safe or useful.
Why hasn't DSIP become a sleep drug?
Half a century after its discovery, the effect never proved robust enough to carry a drug-development program — which is itself a data point about the strength of the signal.
Was the original rabbit experiment flawed?
It was elegant and likely real as far as it went — the problem was downstream: the effect wouldn't replicate robustly across labs and species, the fate of many first findings.
Why does DSIP lack a receptor after 50 years?
Candidate mechanisms never confirmed; binding studies didn't converge. A bioactive peptide without a target after this long usually means weak, indirect or context-dependent activity — consistent with its inconsistent literature.